Search results for "Lymph"

showing 10 items of 4590 documents

Novel Opportunities for Cathepsin S Inhibitors in Cancer Immunotherapy by Nanocarrier-Mediated Delivery

2020

Cathepsin S (CatS) is a secreted cysteine protease that cleaves certain extracellular matrix proteins, regulates antigen presentation in antigen-presenting cells (APC), and promotes M2-type macrophage and dendritic cell polarization. CatS is overexpressed in many solid cancers, and overall, it appears to promote an immune-suppressive and tumor-promoting microenvironment. While most data suggest that CatS inhibition or knockdown promotes anti-cancer immunity, cell-specific inhibition, especially in myeloid cells, appears to be important for therapeutic efficacy. This makes the design of CatS selective inhibitors and their targeting to tumor-associated M2-type macrophages (TAM) and DC an attr…

0301 basic medicineT-Lymphocytesmedicine.medical_treatmentReview02 engineering and technologyCancer immunotherapyNeoplasmsTumor-Associated MacrophagesTumor Microenvironmentcysteine proteaseMolecular Targeted TherapySulfoneslcsh:QH301-705.5Cathepsin SAntigen PresentationDrug Carrierscysteine cathepsintumor-associated macrophage (TAM)ChemistrynanoparticleAzepinesDipeptidesGeneral Medicine021001 nanoscience & nanotechnologyGene Expression Regulation NeoplasticImmunotherapy0210 nano-technologydendritic cellAntigen presentationAntineoplastic AgentsTumor-associated macrophageM2 macrophage03 medical and health sciencesLeucinemedicineHumansProtease InhibitorsAntigen-presenting celltargetingtherapypolarizationTumor microenvironmentT cellDendritic CellsDendritic cellextracellular matrix (ECM)Cathepsinstumor associated macrophage030104 developmental biologylcsh:Biology (General)antigen presenting cellCancer researchNanoparticlesimmune suppressionNanocarriers
researchProduct

Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery

2020

Successful outcome of immune checkpoint blockade in patients with solid cancers is in part associated with a high tumor mutational burden (TMB) and the recognition of private neoantigens by T-cells. The quality and quantity of target recognition is determined by the repertoire of ‘neoepitope’-specific T-cell receptors (TCRs) in tumor-infiltrating lymphocytes (TIL), or peripheral T-cells. Interferon gamma (IFN-γ), produced by T-cells and other immune cells, is essential for controlling proliferation of transformed cells, induction of apoptosis and enhancing human leukocyte antigen (HLA) expression, thereby increasing immunogenicity of cancer cells. TCR αβ-dependent therapies should account f…

0301 basic medicineT-Lymphocytesmedicine.medical_treatmentprecision medicineImmunologyEpitopes T-LymphocyteReviewHuman leukocyte antigenBiologyMajor histocompatibility complexCancer Vaccines03 medical and health sciencesLymphocytes Tumor-Infiltrating0302 clinical medicineImmune systemAntigenAntigens NeoplasmantigensNeoplasmsmedicineAnimalsHumansImmunology and AllergyT-cell receptorTumor microenvironmentneoepitopesWhole Genome SequencingT-cellsT-cell receptorComputational BiologyImmunotherapyTILRC581-607vaccinationImmune checkpoint030104 developmental biology030220 oncology & carcinogenesisCancer researchbiology.proteinimmunotherapyImmunologic diseases. AllergyFrontiers in Immunology
researchProduct

Activation and selective IL-17 response of human Vγ9Vδ2 T lymphocytes by TLR-activated plasmacytoid dendritic cells.

2016

// Elena Lo Presti 1,2 , Nadia Caccamo 1,2 , Valentina Orlando 1,2 , Francesco Dieli 1,2 and Serena Meraviglia 1,2 1 Central Laboratory of Advanced Diagnosis and Biomedical Research (CLADIBIOR), University of Palermo, Palermo, Italy 2 Department of Biopathology and Medical Biotechnologies (DIBIMED), University of Palermo, Palermo, Italy Correspondence to: Serena Meraviglia, email: // Keywords : γδ T cells, plasmacytoid dendritic cells, IL-17, TLR activation, proliferation, Immunology and Microbiology Section, Immune response, Immunity Received : July 20, 2016 Accepted : August 02, 2016 Published :August 31, 2016 Abstract Vγ9Vδ2 T cells and plasmacytoid dendritic cells (pDCs) are two distinc…

0301 basic medicineTLR activationCellCell CommunicationLigandsLymphocyte Activation0302 clinical medicineT-Lymphocyte SubsetsCoculture TechniqueAntigen PresentationInterleukin-17Research Paper: Immunologyhemic and immune systemsIL-17medicine.anatomical_structurePhenotypeOncologyplasmacytoid dendritic cellsImmunology and Microbiology SectionInterleukin 17HumanCell typeproliferationCD40 LigandLigandBiologyDendritic Cellγδ T cells03 medical and health sciencesInducible T-Cell Co-Stimulator LigandInterferon-gammaImmune systemImmunityplasmacytoid dendritic cellmedicineHumansImmune responseCell Proliferationγδ T cellCD40Innate immune systemImmunityTLR9Dendritic CellsReceptors OX40Coculture TechniquesImmunity Innate030104 developmental biologyImmunologybiology.proteinLeukocytes MononuclearCpG IslandsCpG IslandImmunologic Memory030215 immunologyOncotarget
researchProduct

2017

Bruton's tyrosine kinase (BTK) was initially discovered as a critical mediator of B cell receptor signaling in the development and functioning of adaptive immunity. Growing evidence also suggests multiple roles for BTK in mononuclear cells of the innate immune system, especially in dendritic cells and macrophages. For example, BTK has been shown to function in Toll-like receptor-mediated recognition of infectious agents, cellular maturation and recruitment processes, and Fc receptor signaling. Most recently, BTK was additionally identified as a direct regulator of a key innate inflammatory machinery, the NLRP3 inflammasome. BTK has thus attracted interest not only for gaining a more thoroug…

0301 basic medicineToll-like receptorInnate immune systembiologyImmunologyX-linked agammaglobulinemiaInflammasomeDendritic cellAcquired immune systemmedicine.diseaseCell biology03 medical and health sciences030104 developmental biologyimmune system diseaseshemic and lymphatic diseasesImmunologymedicinebiology.proteinImmunology and AllergyBruton's tyrosine kinaseTyrosine kinasemedicine.drugFrontiers in Immunology
researchProduct

11q Deletion or ALK Activity Curbs DLG2 Expression to Maintain an Undifferentiated State in Neuroblastoma

2020

High-risk 11q deleted neuroblastomas typically display undifferentiated/poorly differentiated morphology. Neuroblastoma is thought to develop from Schwann cell precursors and undifferentiated neural crest (NC) derived cells. It is therefore vital to understand mechanisms involved in the block of differentiation. We identify an important role for oncogenic ALK-ERK1/2-SP1 signaling in maintenance of undifferentiated NC-derived progenitors via repression of DLG2, a tumor suppressor in neuroblastoma. DLG2 is expressed in the ‘bridge signature’ that represents the transcriptional transition state when neural crest cells or Schwann Cell Precursors become chromaffin cells of the adrenal gland. We …

0301 basic medicineTranscription GeneticCarcinogenesisChromaffin CellsRetinoic acidlaw.inventionNeuroblastomachemistry.chemical_compound0302 clinical medicinelawNerve Growth FactorMedicine and Health Sciencesretinoic acidAnaplastic Lymphoma Kinaselcsh:QH301-705.5NeuronsMice Inbred BALB CNeural crestCell DifferentiationPrognosisCandidate Tumor Suppressor GeneDLG2Up-RegulationCell biologyGene Expression Regulation NeoplasticERKPhenotypeTreatment Outcomemedicine.anatomical_structureFemaleChromosome Deletiontumor suppressorMAP Kinase Signaling SystemSp1 Transcription FactorSchwann cellGenetics and Molecular BiologyTretinoinBiologyGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesAdrenergic AgentsCell Line TumorNeuroblastomamedicineAnimalsHumansProgenitor cellGenePsychological repressionCell ProliferationChromosomes Human Pair 11Tumor Suppressor Proteinsmedicine.disease030104 developmental biologyALKlcsh:Biology (General)chemistryTrk receptorGeneral BiochemistrySuppressorSchwann CellsGuanylate Kinases030217 neurology & neurosurgerySSRN Electronic Journal
researchProduct

Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1

2021

Abstract Richter’s transformation (RT) is an aggressive lymphoma that occurs upon progression from chronic lymphocytic leukemia (CLL). Transformation has been associated with genetic aberrations in the CLL phase involving TP53, CDKN2A, MYC, and NOTCH1; however, a significant proportion of RT cases lack CLL phase–associated events. Here, we report that high levels of AKT phosphorylation occur both in high-risk CLL patients harboring TP53 and NOTCH1 mutations as well as in patients with RT. Genetic overactivation of Akt in the murine Eµ-TCL1 CLL mouse model resulted in CLL transformation to RT with significantly reduced survival and an aggressive lymphoma phenotype. In the absence of recurren…

0301 basic medicineTumor microenvironmentChronic lymphocytic leukemiaImmunologyNotch signaling pathwayMedizinAggressive lymphomaCell BiologyHematologyBiologymedicine.diseaseBiochemistrySomatic evolution in cancerLymphoma03 medical and health sciencesLeukemia030104 developmental biology0302 clinical medicineimmune system diseaseshemic and lymphatic diseasesmedicineCancer researchneoplasmsProtein kinase B030215 immunology
researchProduct

Cytomegalovirus vector expressing RAE-1γ induces enhanced anti-tumor capacity of murine CD8+ T cells

2017

Designing of CD8 T cell vaccines which would provide protection against tumors is still considered a great challenge in immunotherapy. Here we show a robust potential of a cytomegalovirus (CMV) vector expressing the NKG2D ligand RAE-1γ as CD8 T cell-based vaccine against malignant tumors. Immunization with the CMV vector expressing RAE-1γ delayed tumor growth or even provided complete protection against tumor challenge in both prophylactic and therapeutic settings. Moreover, a potent tumor control in mice vaccinated with this vector can be further enhanced by blocking the immune checkpoints TIGIT and PD-1. Expression of RAE-1γ by the CMV vector potentiated expansion of KLRG1+ CD8 T cells wi…

0301 basic medicineTumor vaccine [RAE-1γ]medicine.medical_treatmentT cellImmunologyGenetic VectorsProgrammed Cell Death 1 ReceptorMelanoma ExperimentalCytomegalovirusEpitopes T-LymphocyteBiologyCD8-Positive T-LymphocytesCancer VaccinesArticleCMV vectorNKG2DImmunomodulation03 medical and health sciencesMiceImmune systemTIGITKLRG1+ CD8+ T cellsNeoplasmsmedicineImmunology and AllergyCytotoxic T cellAnimalsHumansRAE-1γ : Tumor vaccineLectins C-TypeReceptors ImmunologicαTIGIT ; CMV vector ; KLRG1+ CD8+ T cells ; NKG2D ; RAE-1γ : Tumor vaccineBIOMEDICINE AND HEALTHCARE. Basic Medical Sciences.Membrane ProteinsImmunotherapyNKG2DVirology3. Good healthKiller Cells NaturalDisease Models Animal030104 developmental biologymedicine.anatomical_structureImmunizationAnimals NewbornFemaleαTIGITImmunotherapyBIOMEDICINA I ZDRAVSTVO. Temeljne medicinske znanosti.CD8
researchProduct

An overview on anti-tubulin agents for the treatment of lymphoma patients

2020

Anti-tubulin agents constitute a large class of compounds with broad activity both in solid tumors and hematologic malignancies, due to the interference with microtubule dynamics. Since microtubules play crucial roles in the regulation of the mitotic spindles, the interference with their function usually leads to a block in cell division with arrest at the metaphase/anaphase junction of mitosis, followed to apoptosis. This explains the reason why tubulin-binding agents (TBAs) proved to be extremely active in patients with cancer. Several anti-tubulin agents are indicated in the treatment of patients with lymphomas both alone and in combination chemotherapy regimens. The article reviews the …

0301 basic medicineVinca alkaloidsLymphomaMitosisAntineoplastic AgentsApoptosismacromolecular substancesMicrotubulesAntibody drug conjugatesTaxanes03 medical and health sciences0302 clinical medicineTubulinMicrotubulemedicineAnimalsHumansMaytansinePharmacology (medical)MetaphaseMitosisAnaphasePharmacologybiologybusiness.industryCancerCombination chemotherapymedicine.diseaseTubulin ModulatorsLymphoma030104 developmental biologyTubulinEpothilones030220 oncology & carcinogenesisbiology.proteinCancer researchDolastatinsbusinessPharmacology & Therapeutics
researchProduct

Effect of Buthionine Sulfoximine on the Sensitivity to Doxorubicin of Parent and MDR Tumor Cell Lines

1994

We have studied the interaction of glutathione-depleting concentrations of buthionine sulfoximine (BSO) with the anti-proliferative activity of doxorubicin (DXR) in three tumor lines, the mouse B16 melanoma. Friend erythroleukemia and the human K562 leukemia, both as DXR-sensitive and-resistant (with typical multidrug resistance) variants. BSO significantly enhanced the DXR effects in the wild-type Friend and K562 leukemias, and especially in the drug-resistant subline of Friend leukemia. BSO did not modify DXR accumulation and retention in the latter clone. Moreover, neither BSO nor verapamil used alone completely reversed the resistance to DXR of this cell line; their combination was more…

0301 basic medicineVincristineFriend leukemia030106 microbiologyPharmacologyMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMethionine Sulfoximinehemic and lymphatic diseasesTumor Cells CulturedmedicineAnimalsHumansPharmacology (medical)DoxorubicinButhionine sulfoximineButhionine SulfoximinePharmacologyChemistryDrug SynergismGlutathionemedicine.diseaseGlutathioneDrug Resistance MultipleMultiple drug resistanceLeukemiaInfectious DiseasesOncologyDoxorubicinVincristine030220 oncology & carcinogenesismedicine.drugK562 cellsJournal of Chemotherapy
researchProduct

Deciphering human γδ T cell response in cancer: Lessons from tumor‐infiltrating γδ T cells

2020

The finding that γδ T cells are present among tumor-infiltrating lymphocytes in humans suggests they participate in tumor immune surveillance, but their relevance is unclear because the relative abundance of tumor-infiltrating γδ T cells correlates with positive or negative, or even do not correlate with prognosis. This likely depends on the fact that tumor-infiltrating γδ T cells may play substantially different effector or regulatory functions, and correlation with patient's prognosis relies on distinct γδ T cell subsets in the context of the tumor. There is interest to exploit γδ T cells in tumor immunotherapy, but to make this approach successful there is urgent need to fully understand…

0301 basic medicine[SDV]Life Sciences [q-bio]medicine.medical_treatmentT cellImmunologyContext (language use)BiologyTumor-infiltrating lymphocytesclinical correlationcolon cancer tumor microenvironment tumor-infiltrating lymphocytes γδ T lymphocytesClinical correlazion03 medical and health sciencesLymphocytes Tumor-Infiltrating0302 clinical medicineT-Lymphocyte SubsetsNeoplasmsmedicineHumansImmunology and AllergyComputingMilieux_MISCELLANEOUSTumor microenvironmentTumor-infiltrating lymphocytesEffectorCancerReceptors Antigen T-Cell gamma-deltaImmunotherapyGamma-delta T lymphocytesmedicine.diseaseColon cancer3. Good health030104 developmental biologymedicine.anatomical_structureTumor microenvironmentCancer researchEx vivo030215 immunologyImmunological Reviews
researchProduct